THE PHENOMENOLOGY AND TREATMENT OF OBESSIVE-COMPULSIVE DISORDER IN ADULTS

成人强迫症的现象和治疗

• 批准号: 3859817
• 负责人: D L MURPHY
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF MENTAL HEALTH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3859817
• 关键词: buspirone; combination chemotherapy; ergolines; human subject; human therapy evaluation; imipramine; lithium; longitudinal human study; mental disorder chemotherapy; neuroendocrine system; neurotransmitter metabolism; obsessive compulsive disorder; psychobiology; serotonin; serotonin inhibitor; serotonin receptor; triiodothyronine

Controlled treatment studies of patients with obsessive-compulsive disorder (OCD) revealed that the serotonin 5-HT1A receptor partial agonist, buspirone, was as effective as the most well-established therapeutic agent in OCD, clomipramine. However, the addition of buspirone to clomipramine in a group of OCD patients in partial remission yielded no further improvement, suggesting that other ways to modulate brain serotonergic subsystems are needed, and/or other psychobiologic factors need to be considered in attempts to gain additional therapeutic benefit. Some additional initiatives in this direction utilizing lithium and triiodothyronine together with clomipramine led to minimal further benefit, although such cotreatment has been reported to be of value in depressed patients. Additional evidence regarding the importance of serotonin in OCD came from a study demonstrating that pretreatment with the serotonin antagonist, metergoline, blocked the brief exacerbation of OCD symptoms produced by the 5-HT1C serotonin agonist, m-chlorophenylpiperazine.

强迫症患者的对照治疗研究 （OCD）表明5-羟色胺5-HT1A受体部分激动剂， Buspirone，与最成熟的治疗剂一样有效 在强迫症中，氯米帕明。 但是，添加丁吡啶丙咪胺 在一组OCD患者中，部分缓解没有进一步 改进，表明其他调节脑血清素能的方法 需要子系统，/或其他心理生物学因素需要 考虑为获得额外的治疗益处而考虑。 一些 利用锂和 三碘甲状腺素以及氯米帕明导致最小的好处， 尽管据报道这种共同处理在沮丧中有价值 患者。 有关5-羟色胺在强迫症中的重要性的其他证据 来自一项研究，证明了5-羟色胺的预处理 拮抗剂，恩迪格林阻止了OCD症状的短暂加重 由5-HT1C 5-羟色胺激动剂M-氯苯基哌嗪产生。